Quote:

---

HIV is already committed to the shell corporation Regnum (2 persons) and is not as good as Gilead, NASH 350 mg was mediocre at best, 700 mg won't be good enough to be even competitive and certainly won't be "breakthrough" -- no quality BP wants an uncompetitive drug. Brazil CoV is just interim at best if they even even meet any recruiting requirements.

---

I see you're playing the idiot again and posting misleading statements. Gilead doesn't have an HIV drug that doesn't develop resistance. Leronlimab's 91% efficacy at 700mg is as good or better without the very bad side effects.

What does "interim at best" even mean? You have no idea of what the results will be because the trial hasn't released any data yet.